On May 24, 2023 Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, reported it will be presenting three posters at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) Annual Meeting being held in Hawaii from May 22-26, 2023 (Press release, Perspective Therapeutics, MAY 24, 2023, View Source [SID1234632000]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to present our latest research on targeted alpha therapies at the Society of Radiopharmaceutical Sciences annual meeting. Our scientists and collaborators have made significant progress in this field, and we are excited to share our findings with the wider scientific community. We believe that targeted alpha therapies have the potential to revolutionize cancer treatment, and we are committed to advancing this promising new approach." said Thijs Spoor, Perspective Therapeutics’ Chief Executive Officer.
Michael Schultz, Perspective Therapeutics’ Chief Science Officer added, "I would like to thank our fabulous team of scientists and our collaborators for their relentless dedication to developing the best possible applications for our technology platform. This enables the best possible isotopes to be utilized to keep moving us toward the goal of improved cancer therapies. We are looking forward to discussing our findings with the global radiopharmaceutical science community at iSRS."
Poster Presentation Summaries
Poster presentation #1: "Low-dose targeted alpha therapy induces strong anti-tumor effectiveness in combination with immune checkpoint inhibitors"
This poster shares the ongoing work by Perspective Therapeutics’ scientists and collaborators at the University of Wisconsin exploring the potential of targeted alpha therapies (TAT) in combination with established immune checkpoint inhibitor (ICI) therapies in preclinical melanoma models. The presented results confirm and extend the previously published preclinical work by the team, revealing long term curative responses from the combination of immunotherapies and TAT. In conclusion:
When combined with dual ICIs, low doses of [212Pb]VMT01 was more efficacious and resulted in complete tumor remission when compared with mid- and high-administered radioactivity doses. The immunostimulatory effects of TAT may not be linear to radiation dose. Therefore, the ideal dose of TAT that induces strongest anti-tumor efficacy with ICIs in melanoma needs to be further elucidated.
The poster will be presented during Poster Session 2A: Radionuclide Therapy on Wednesday May 24, 5:30PM – 6:15 PM HST in Kalākaua Ballroom A, by Samuel Rodman PhD, Research Scientist, Perspective Therapeutics.
Poster presentation #2: "Optimizing 203Pb cyclotron production and availability: The ideal SPECT imaging theranostic partner for 212Pb targeted alpha therapy"
This poster discusses the Company’s continued work with its multi-institutional collaborators in order to improve the production methods for the SPECT isotope Pb-203 as part of its matched isotope theranostic pairing with Pb-212 targeted alpha therapy. The goal of this work is to ensure the availability of isotope supplies with high purity for ongoing imaging studies and for the Company’s pipeline of emerging products. In conclusion:
Nuclear medicine centers with a 24 MeV cyclotron can produce and purify large 203Pb activities sufficient for clinical applications. This represents an attractive route to produce 203Pb for theranostic use as a SPECT radionuclide alongside 212Pb targeted alpha therapy. The [203Pb]Pb(OAc)2 product can be produced with high radiochemical purity – and radiolabeling experiments demonstrate strong potential for preclinical and clinical 203Pb radiopharmaceutical applications.
The poster will be presented during Poster Session 2A: Targetry on Wednesday May 24, 5:30PM – 6:15 PM HST in Kalākaua Ballroom A as presented by Bryce Nelson, University of Alberta.
Poster presentation #3: "Analysis of Radiochemical Stability and In Vivo Distribution of Recoiled 213Bi from [225Ac]Ac-DOTATATE in Preclinical Model"
Targeted alpha-particle radiotherapies (TATs) have been evolving as promising treatments in management of cancers. Within this context, due to four alpha-particle emissions along the decay chain, 225Ac-based TATs have demonstrated superior tumor-killing efficacy compared with beta-particle emitters. However, the complex decay and recoil of daughters following the alpha-particle emission results in ambiguity in understanding the toxicity of these radiopharmaceuticals. In this study, we aimed to assess the ingrowth and radiochemical stability of 213Bi and potential in vivo redistribution following the injection of [225Ac]Ac-DOTATATE in preclinical model. In conclusion:
Although 213Bi can be labeled initially, decoupling of ingrown free 213Bi was inevitable with the decay of [225Ac]Ac-DOTATATE and significantly different biodistributions between the labeled 225Ac product and free213Bi are observed. Therefore, it is hypothesized that the radiochemical stability and biodistribution of recoiled daughters need to be characterized to better understand the potential toxicity resulted from injection of 225Ac -based TATs.
The poster will be presented during Poster Session 3: Radionuclide Therapy on Friday May 26, 2:45 PM – 3:30 PM HST in Kalākaua Ballroom A by Dijie Liu PhD DVM, Principle Research Scientist.